脂质体制剂两性霉素 B 治疗 HIV 阴性患者的黏膜利什曼病。
Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
机构信息
Department of Infectious and Parasitic Diseases, University of São Paulo, Medical School, São Paulo, SP, Brazil.
出版信息
Trans R Soc Trop Med Hyg. 2014 Mar;108(3):176-8. doi: 10.1093/trstmh/tru011.
BACKGROUND
Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined.
METHODS
We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day.
RESULTS
Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg.
CONCLUSION
Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.
背景
评估脂质体两性霉素 B（LAB）治疗黏膜利什曼病（ML）患者疗效的研究在文献中非常罕见，尚未确定最佳剂量方案。
方法
我们对 16 例接受 LAB 治疗的 ML 患者的记录进行了回顾性和描述性分析。LAB 的平均日剂量为 2.5mg/kg/天。
结果
16 例患者中有 14 例（88%）观察到病变愈合。排除 2 例治疗失败病例，累积剂量的平均值为 2265mg 和 33mg/kg。
结论
脂质体两性霉素 B 的累积剂量为 30 至 35mg/kg 时，能够达到 100%的疗效。
Zotero 插件